Experience of successful use of rituximab in treatment-resistant membranous nephropathy
M. M. Batiushin,
N. A. Bronovitskaya,
E. A. Sinelnik,
N. B. Bondarenko,
A. V. Razina,
K. R. Bogomolova https://doi.org/10.21886/2712-8156-2020-1-3-91-94
Abstract
The article presents as an introduction a short review on the problem of membranous nephropathy. A patient suffering from membranous nephropathy that is resistant to traditional therapy with glucocorticoids and cyclophosphane, as well as cyclosporine, was selected as a clinical case. The use of rituximab at a dose of 375 mg/m2 twice with a difference of one week led to the development of remission in the patient, normalization of clinical and laboratory parameters. No side effects of rituximab were detected.
About the Authors
M. M. Batiushin
Rostov State Medical University
Russian Federation
Russian Federation
Mikhail M. Batyushin, Dr. Sci. (Med.), Professor, Professor of the Department of Internal Diseases No. 2
Rostov-on-Don
N. A. Bronovitskaya
Rostov State Medical University
Russian Federation
Russian Federation
Natalya A. Bronovitskaya, Cand. Sci. (Med.), nephrologist of the nephrological department, assistant of the department of general medical practice (family medicine)
Rostov-on-Don
E. A. Sinelnik
Rostov State Medical University
Russian Federation
Russian Federation
Elena A. Sinelnik, Assistant of the Department of Pathological Anatomy
Rostov-on-Don
N. B. Bondarenko
Rostov State Medical University
Russian Federation
Russian Federation
Nikolay B. Bondarenko, nephrologist of the nephrology department
Rostov-on-Don
A. V. Razina
Rostov State Medical University
Russian Federation
Russian Federation
Alexandra V. Razina, Cand. Sci. (Med.), Nephrologist of the Nephrology Department
Rostov-on-Don
K. R. Bogomolova
Rostov State Medical University
Russian Federation
Russian Federation
Kristina R. Bogomolova, 4th year student of the pediatric faculty
Rostov-on-Don
References
1. Bobkova I. N., Kakhsurueva P. A., Stavrovskaya E. V. Idiopathic membranous nephropathy: evolution in understanding the problem. Therapeutic archive. 2016;88(6):89-94
2. Dobronravov V. A., Lapin S. V., Lazareva N. M. et al. Circulating antibodies to the phospholipase A2 receptor in primary membranous nephropathy. Nephrology. 2012;16(4):39-44
3. Burbelo P.D., Joshi M., Chaturvedi A. et al. Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. J Am Soc Nephrol. 2020;31(1):208-217. doi: 10.1681/ASN.2019050538.
4. Couser W.G. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. doi: 10.2215/CJN.11761116.
5. Bomback A.S., Fervenza F.C. Membranous Nephropathy: Approaches to Treatment. Am J Nephrol. 2018;47 Suppl 1:30-42. doi: 10.1159/000481635.
6. Fervenza F.C., Appel G.B., Barbour S.J. et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi: 10.1056/NEJMoa1814427.
7. Zhang J., Bian L., Ma F.Z. et al. Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2018;22(22):8021-8029. doi: 10.26355/eurrev_201811_16431.
Supplementary files
Review
For citations:
Batiushin M.M., Bronovitskaya N.A., Sinelnik E.A., Bondarenko N.B., Razina A.V., Bogomolova K.R. Experience of successful use of rituximab in treatment-resistant membranous nephropathy. South Russian Journal of Therapeutic Practice. 2020;1(3):91-94. (In Russ.) https://doi.org/10.21886/2712-8156-2020-1-3-91-94
Views:
742
Email this article 